



University of  
Nottingham

UK | CHINA | MALAYSIA

# MILD Fibrosis Meeting 2019

The Great Hall  
Trent Building  
University Park Campus  
Nottingham  
NG7 2RD

**15<sup>th</sup> November**



INJUSTIS\_study  
#MILD2019



[www.injustisstudy.org](http://www.injustisstudy.org)

# MILD Fibrosis Meeting 2019 Programme

09:00-09:30	Registration & refreshments
09:30-10:00	Epidemiology of ILD: Dr John Hutchinson (Kings Mill, UK)
10:00-10:30	Pathogenesis of fibrotic lung disease: Prof Gisli Jenkins (Nottingham, UK)
10:30-11:00	Refreshments
11:00-11:30	Biomarkers for managing ILDs: Prof Eric White (Ann Arbor, USA)
11:30-12:00	Non-pharmacological treatment for ILD: Geraldine Burge (Birmingham, UK)
12:00-13:00	Lunch & refreshments – Served in the Senate Chamber
13:00-13:30	Lung transplant for ILD patients: Dr Richard Thompson (Birmingham, UK)
13:30-14:00	The INJUSTIS study: Dr Fasi Khan (Nottingham, UK)
14:00-14:30	Refreshments
14:30-15:15	RA-ILD: Dr Leticia Kawano-Dourado (Sao Paulo, Brazil)
15:15-16:00	Treatment of non-fibrotic ILDs: Prof Bibek Goptu (Leicester, UK)
16:00-16:30	Refreshments and feedback
<b>Sponsorship:</b>	Meeting costs have been sponsored by an unrestricted educational grant from Boehringer Ingelheim Ltd.

# MILD Fibrosis Meeting 2019

## Speaker biographies

### **Geraldine Burge (Birmingham, UK): Non-pharmacological treatment for ILD**

Geraldine Burge MSc ILD specialist nurse at University hospitals Birmingham NHS trust across 4 sites, trained at Westminster hospital before starting postgraduate courses in cardio thoracic medicine, Jungian psychology, palliative care and teaching. Geraldine has worked as a Research nurse in interstitial lung disease since 2002 completing studies of Interferon gamma, Pirfenidone and Nintedanib before becoming one of the first NHS ILD clinical nurse specialists. She worked for NICE 2009 scoping exercise for IPF, 2011-2013, NICE IPF Guideline Development Group and again reviewing the guidance 2016. She runs the local ILD patient support group and works as a volunteer for Action for Pulmonary Fibrosis Charity, and British Lung Foundation Health care professional.



She has been the Chairman of the nursing group of the European Respiratory Society Assembly 9.03 (1997-1999.), whilst working with the ATS nursing group reviewing abstracts for their congresses. Geraldine also worked as secretary to Assembly 9 (2009-2012) sitting in the European School of Respiratory Medicine; and currently sit on ERS Research Fellowship grant committee. She has sat on numerous Advisory boards for ILD. Geraldine was a founding director and chairman of the Interstitial lung Disease Interdisciplinary network ILD-INN.2015-2017 and currently the West Midlands regional ILD-INN lead.

### **Prof Bibek Gooptu (Leicester, UK): Treatment of non-fibrotic ILDs**

Prof Gooptu's research defines and therapeutically targets molecular mechanisms of diseases within one or both of the following categories: (i) those driven by protein misfolding / conformational change; (ii) those causing chronic lung disease (COPD and ILD).

A longstanding interest has been in studying the structure and biology of the serpin (serine protease inhibitor) superfamily of proteins, and the diseases that arise from mutations causing their misfolding and/or conformational change (serpinopathies). The combination of biochemical studies, genotype: phenotype correlation in humans, and X-ray crystallography led to key early insights. More recently, the Gooptu group has applied NMR, native MS and single particle EM to understand how altered structural dynamics are critical to pathological behaviour in serpins, how serpins self-associate into polymers, and to develop small molecules as therapies. In parallel, proteomic studies have defined in unprecedented detail the subcellular consequences of serpin misfolding and conformational change in cell models of the archetypal serpinopathy, 1-antitrypsin deficiency. An ongoing research collaboration further probes how 1-antitrypsin deficiency results in impaired immunomodulation. These studies are supported by the Wellcome Trust, Alpha-1 Foundation, and MRC and CASE studentships.

Prof Gooptu is now using similar multi-platform approaches to understand how interactions of the chimaeric protein galectin-3 at the surface of epithelial and fibroblast cells mediate fibrosis in multiple organs. The disease focus is particularly on the devastating lung condition idiopathic pulmonary fibrosis (IPF). This work is currently supported by start-up funding from the University of Leicester and makes use of the state-of-the-art basic and clinical research facilities at the LISCB, the Advanced Imaging Facility and the NIHR Leicester Respiratory Biomedical Research Centre.



# MILD Fibrosis Meeting 2019

## Speaker biographies

### **Dr John Hutchinson (Kings Mill, UK): Epidemiology of ILD**

Dr John Hutchinson is a Consultant Respiratory Physician based at King's Mill Hospital, part of Sherwood Forest Hospitals NHS Foundation Trust in central Nottinghamshire. He completed his PhD in the epidemiology of idiopathic pulmonary fibrosis under the supervision of Professor Richard Hubbard in Nottingham, with work focusing on global incidence and mortality trends, and the risks of surgical lung biopsy in diagnosing ILD. He is a member of the British Thoracic Society ILD Registry Steering Group.

### **Prof Gisli Jenkins (Nottingham, UK): Pathogenesis of fibrotic lung disease**

Professor Gisli Jenkins is an NIHR Research Professor and Professor of Experimental Medicine at the University of Nottingham and joint Editor-in-Chief of Thorax. He completed his medical training at University of Southampton before undertaking postgraduate training in Respiratory Medicine in London. During this time he undertook basic scientific training funded by an ARC Fellowship and obtained a PhD in Biochemistry from UCL before doing post-doctoral studies at UCSF as part of an ARC Clinician Scientist Fellowship.

His clinical and research focus is on interstitial lung disease, and pulmonary fibrosis in particular. He is academic lead at the Nottingham Interstitial Lung Diseases Unit and runs the pulmonary fibrosis work strands for the MRC Nottingham Molecular Pathology Node, and is the ILD subdomain lead for the Genomics England Clinical Interpretation Partnership in Respiratory Medicine. His research has been published in leading academic journals including the Journal of Clinical Investigation, Lancet Respiratory Medicine, Nature Communications and Science Signalling.

Professor Jenkins' is a Trustee of the patient charity Action for Pulmonary Fibrosis and his research group has received funding from Academic organisations including the Wellcome Trust, the Medical Research Council, Arthritis Research UK and Asthma UK as well as industrial contracts with Biogen, Galecto, GlaxoSmithKline, MedImmune and Novartis.

Conflicts of Interest are: Sponsored Research Agreements with Astra Zeneca, Biogen, and Galecto, Advisory Boards for Boehringer Ingelheim, NuMedii, Promedior, and Redex, and lecture fees and consultancy for Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Heptares, Pliant, and Roche. He is also a trustee for Action for Pulmonary Fibrosis.



### **Dr Leticia Kawano-Dourado (Sao Paulo, Brazil): RA-ILD**

Dr Kawano Dourado, MD, is a Pulmonologist who specialised in Interstitial Lung Diseases at the University of Sao Paulo and Clinical Researcher for the Research Institute at Hospital do Coracao. She is BERTHA study Principal Investigator: Multicentric Observational Cohort Study on RA-ILD Progression.



# MILD Fibrosis Meeting 2019

## Speaker biographies

### **Dr Fasi Khan (Nottingham, UK): The INJUSTIS study**

Dr Fasi Khan is a clinical research fellow (and specialist registrar in Respiratory medicine) undertaking his research at the University of Nottingham under the supervision of Professor Gisli Jenkins. His PhD is around identifying biomarkers that may predict progressive fibrotic lung disease. He is heavily involved with the INJUSTIS study, and has recently been appointed as a member of the British Thoracic Society Interstitial and rare Lung Disease Advisory Group



### **Dr Richard Thompson: (Birmingham, UK): Lung transplant for ILD patients**

Dr Richard Thompson is a Consultant Respiratory Physician. He trained in London but was lucky enough to escape to Birmingham 15 years ago. His speciality interests include lung transplantation, infection in the immunocompromised and pleural disease.



### **Prof Eric White (Ann Arbor, USA): Biomarkers for managing ILDs**

Eric S. White, MD, MS, ATSF is a Professor of Internal Medicine at the University of Michigan Medical School, where he also serves as the Director of Translational Interstitial Lung Disease Research. He received his MD degree from the State University of New York Health Science Center in Brooklyn, and a Master of Science degree in Clinical Research Design and Statistical Analysis from the University of Michigan School of Public Health. His research interests include biomarker discovery in interstitial lung diseases and biorepository development and management. He has served as a consultant, as a Steering Committee member, and member of Data Safety Monitoring Boards for clinical trials focused on interstitial lung disease. He continues to care for patients with all interstitial lung diseases, with a focus on IPF, connective tissue disease-associated ILD, and sarcoidosis.



Professor White serves as a member of the Medical Advisory Board of the Pulmonary Fibrosis Foundation, as well as Associate Editor of the American Journal of Respiratory and Critical Care Medicine and on the editorial board of the American Journal of Respiratory Cell and Molecular Biology. He currently holds the position of International Conference Committee Chair and member of the Board of Directors for the American Thoracic Society.



# INJUSTIS


It's Not JUST Idiopathic Pulmonary Fibrosis Study



University of  
Nottingham  
UK | CHINA | MALAYSIA



patient **M** power  
empowering better outcomes



Action for  
Pulmonary  
Fibrosis



Nottingham  
Respiratory  
Research Unit

• Asthma • COPD • ILD • Lung Infection •